Eli Lilly's investigational immunology drug ebglyss met both primary and secondary endpoints at 16 weeks in the Phase 3b ADtouch trial, the company announced on September 30, 2026. The study enrolled patients with moderate-to-severe atopic dermatitis localized to the hands and feet — a presentation where skin clearance, itch and pain carry outsized functional impact.

The trial demonstrated rapid and significant improvements across three domains after 16 weeks of treatment: skin clearance, itch, and pain. Ebglyss outperformed placebo on each measure in the moderate-to-severe hand and foot atopic dermatitis population.

One endpoint stands out for its design rather than its magnitude. Patient satisfaction, measured with the Atopic Hand Dermatitis Clearance Satisfaction scale, came in significantly higher among ebglyss-treated patients than among placebo recipients. Lilly positions this as a pioneering patient-centric metric in this therapeutic area — a departure from clinician-scored clearance measures that dominate atopic dermatitis trials.

Lilly will present the full ADtouch dataset at the European Academy of Dermatology and Venereology Congress in Vienna, running September 30 through October 3, 2026. The congress timing gives European dermatologists first access to the detailed efficacy and safety numbers behind the topline announcement.

Why the indication matters

Hand and foot atopic dermatitis represents a substantial unmet need in dermatology, according to the company's framing of the results. Localization on the palms and soles complicates daily function in ways that body-surface-area metrics understate, and patients with isolated hand and foot disease are frequently excluded from or underrepresented in the pivotal programs that shaped the current treatment landscape.

Ebglyss already sits within Lilly's immunology portfolio alongside Taltz. The broader Lilly pipeline spans cardiometabolic health, oncology, immunology and neuroscience, with key marketed products including Mounjaro, Trulicity and Verzenio. The company carries a market capitalization of $1.12 trillion.

Market context

The positive readout arrives against a favorable financial backdrop for the Indianapolis-based manufacturer. GuruFocus's proprietary GF Value metric places Lilly at roughly 24.1% below estimated fair value, with a GF Value of $1,561.18 versus a market price of $1,184.63. The stock's trailing twelve-month price-to-earnings ratio sits at 40.25x, compressed relative to its five-year median of 53.19x.

Lilly scores 96 out of 100 on the GF Score composite, with perfect 10/10 sub-ranks in profitability and growth. Operating margins run at 49.72%, and earnings grew 81.6% year-over-year. Financial strength ranks 6/10 — supported by an Altman Z-Score of 7.97 but tempered by recent debt issuance — and momentum also ranks 6/10.

Institutional positioning is mixed but net positive. Twenty-five premium gurus tracked by GuruFocus hold the stock, with 12 adding and 10 trimming positions recently. Insider activity tells a different story: no insider purchases over the past 12 months, and insider sales totaling $3.46 billion in that window, with no purchases reported in the last three months.

What to watch

For dermatologists, the EADV presentations will clarify whether the satisfaction-scale signal holds up alongside conventional clearance endpoints, and what the 16-week safety profile looks like in this anatomically distinct population. If the detailed data support the topline, ebglyss could expand treatment options in a segment of atopic dermatitis where functional burden has long outpaced available evidence.